Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris
About this trial
In this research, we will evaluate the feasibility of following by remote monitoring, using a connected scale, in hematology patients suffering from myeloma or lymphoma and requiring treatment with chemotherapy. 30 patients will be included in the research and will all use a connected scale for the duration of their participation (7 weeks +/- 1 week). During their participation, patients will be asked to weigh themselves once a day, ideally at a set time. Patient data will be accessible by the medical team via a remote monitoring platform.
Alerts will be generated in the event of abnormal development of certain clinical parameters (weight, heart rate, etc.) allowing early treatment to be implemented by the medical team.
At the end of their participation, we will evaluate patients' support and perception of this tool, as well as the healthcare consequences of the alerts generated by the remote monitoring platform.
Eligibility criteria
Qualifiers
Patient aged 18 and over (male or female)
Patient suffering from aggressive non-Hodgkin's lymphoma or multiple myeloma with a plan for systemic chemotherapy or having started two cycles or less or patient with the need for therapeutic intensification under the cover of autograft in the context of myeloma or lymphoma
Patient who can be contacted by telephone during their participation in the research
Patient able to return home at the end of their initial hospitalization
Disqualifiers
Patient with an estimated life expectancy < 3 months
Patient with moderate to severe cognitive impairment (assessed by MMSE < 20)
Patient with a psychiatric or physical disability that does not allow the use of the device
Patient with a pacemaker
Trial design
Treatments tested in this trial
- Connected scale "Body Comp Pro" from Withings
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Assistance Publique - Hôpitaux de Paris
Lead sponsor
Withings
Collaborator
Source ClinicalTrials.gov